Medicure (MPH) AI Stock Analysis

• Market Cap: C$10.85M
• Dividend Yield: N/A
• Average Volume (3M): 1.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: 24.30%
• EPS Growth: -68.60%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.13
• Shares Outstanding: 10,436,313
• 10 Day Avg. Volume: 717
• 30 Day Avg. Volume: 1,717
• PEG Ratio: -0.83
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 0.42
• P/FCF Ratio: 14.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$1.00 ▼(-3.85% Downside)

Medicure's overall stock score is primarily impacted by its financial performance and valuation. The company faces profitability and cash flow challenges despite a stable balance sheet. Technical analysis suggests a neutral to slightly bearish trend, while the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call and corporate events data limits additional insights.

Medicure Business Overview & Revenue Model

Company Description

Medicure Inc. (MPH) is a Canadian pharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular and metabolic diseases. The company operates primarily in the pharmaceutical sector, specializing in the formulation of prescription medications aimed at improving patient outcomes in chronic conditions. Its core products include the proprietary drug Aggrastat, used in acute coronary syndrome, and other pipeline candidates designed to address unmet medical needs in the cardiovascular space.

How the Company Makes Money

Medicure generates revenue primarily through the sales of its pharmaceutical products, including Aggrastat, which is marketed to hospitals and healthcare providers. The company earns income from product sales, which are driven by prescription volume and market demand. Additionally, Medicure may engage in strategic partnerships and licensing agreements with other pharmaceutical companies to co-develop or market products, contributing to its revenue through upfront payments, milestone payments, and royalties on sales. These partnerships are crucial for expanding its market reach and enhancing its product portfolio, thereby increasing potential earnings.

Medicure Financial Statement Overview

Summary

Medicure's financial performance is mixed. While revenue growth is positive, the company struggles with profitability and cash flow generation. The income statement shows negative net profit and EBIT margins, and cash flow analysis reveals a significant decline in free cash flow growth. The balance sheet is stable with low leverage, but the negative ROE indicates inefficiencies in utilizing equity capital.

Income Statement

Medicure's income statement shows a mixed performance. The company has seen a modest revenue growth rate of 6.93% in the TTM period, but it is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains relatively healthy at 53.95%, indicating some efficiency in production. However, the negative net profit margin of -5.83% highlights ongoing challenges in managing costs and achieving profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.06, suggesting conservative leverage. However, the return on equity is negative at -6.84%, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio is strong, showing a solid capital structure, but the negative ROE points to inefficiencies in utilizing equity capital.

Cash Flow

Cash flow analysis reveals challenges in cash generation, with a significant decline in free cash flow growth by -39.33% in the TTM period. The operating cash flow to net income ratio is positive at 0.15, indicating some ability to convert income into cash. However, the free cash flow to net income ratio of 0.63 suggests limited cash flow relative to net income, which could impact future investments and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.20M	21.91M	21.69M	23.07M	21.74M	11.61M
Gross Profit	12.52M	13.09M	13.99M	16.07M	12.71M	5.13M
EBITDA	1.45M	1.54M	1.27M	3.44M	2.39M	-4.04M
Net Income	-1.35M	-1.04M	-922.00K	1.36M	-727.00K	-6.84M
Balance Sheet
Total Assets	28.41M	29.68M	28.06M	29.90M	28.41M	34.05M
Cash, Cash Equivalents and Short-Term Investments	4.74M	7.19M	6.37M	4.86M	3.69M	2.72M
Total Debt	1.09M	874.00K	544.00K	849.00K	1.17M	1.45M
Total Liabilities	10.11M	8.90M	8.16M	8.89M	10.00M	14.91M
Stockholders Equity	18.31M	20.78M	19.90M	21.00M	18.41M	19.15M
Cash Flow
Free Cash Flow	918.00K	638.00K	1.81M	1.52M	3.17M	-2.24M
Operating Cash Flow	1.47M	1.38M	2.08M	1.83M	3.99M	-2.24M
Investing Cash Flow	-2.73M	-739.00K	-270.00K	-310.00K	-2.69M	-7.24M
Financing Cash Flow	-406.00K	-370.00K	-297.00K	-355.00K	-316.00K	-766.00K

Medicure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MPH, the sentiment is Positive. The current price of 1.04 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.14, and above the 200-day MA of 1.03, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 60.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MPH.

Medicure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TH	61 Neutral	―	―	―	―	5.24%	-7.99%
MDP	57 Neutral	C$86.45M	64.48	0.87%	―	2.14%	-83.06%
CTX	54 Neutral	C$8.43M	-6.56	2.83%	―	26.79%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MPH	49 Neutral	C$10.85M	-3.16	-18.39%	―	24.30%	-68.60%
RVV	46 Neutral	C$4.19M	-0.38	-583.18%	―	―	-84.51%
MVMD	35 Underperform	C$5.29M	―	-132.79%	―	-46.59%	9.48%

Medicure Corporate Events

Medicure Sees Revenue Growth Amidst Challenges in Q3 2025

Medicure reported a significant increase in total net revenue for the quarter ended September 30, 2025, reaching $8.2 million compared to $5.2 million in the same period the previous year. Despite a decrease in AGGRASTAT® sales due to generic competition, the company saw growth in its Marley Drug business and new acquisitions like Gateway and West Olympia Pharmacies. However, the quarter ended with a net loss of $1.4 million, attributed to increased R&D investments and pricing pressures, impacting its overall financial performance.

The most recent analyst rating on (TSE:MPH) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Medicure stock, see the TSE:MPH Stock Forecast page.

Medicure Inc. to Announce Q3 2025 Financial Results

Medicure Inc. announced it will present its financial results for the quarter ended September 30, 2025, via a conference call on November 20, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (TSE:MPH) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Medicure stock, see the TSE:MPH Stock Forecast page.

Medicure Inc’s Pioneering Study on PNPO Deficiency Treatment: A Market Game-Changer?

Study Overview: Medicure Inc (TSE:MPH) is conducting a clinical study titled ‘Study of Pyridoxal 5′-Phosphate for the Treatment of Patients With PNPO Deficiency.’ The study aims to evaluate the effectiveness of oral Pyridoxal 5′-Phosphate (P5P) in treating patients with Pyridox(am)ine 5′-Phosphate Oxidase (PNPO) deficiency, a condition with unmet pharmaceutical needs. This study is significant as it addresses the lack of commercially available pharmaceutical-grade P5P.